Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 6/20 | 1.00 |
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 1.00 |
| ▸ | GRIN2D known ✓ | O15399 | 5/20 | 1.00 |
| ▸ | GRIN3B known ✓ | O60391 | 5/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 5/20 | 1.00 |
| ▸ | GRIN2C known ✓ | Q14957 | 5/20 | 1.00 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 0.93 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL20409394 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL15672299 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL21309814 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL4098 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL15532073 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL3642447 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL23859927 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL8996708 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL17559292 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL5569374 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090540-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4399196-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023039532-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | GRIN1 2513/4885GRIN2A 2574/4885GRIN2D 3633/4885 |
| US-20250090540-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | GRIN1 2964/4885GRIN2A 3158/4885GRIN2D 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.